东诚药业(002675.SZ)子公司蓝纳成获得放射性药品生产许可证

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its subsidiary, Yantai Lanacheng Biotechnology Co., Ltd. (referred to as "Lanacheng"), has received the "Radioactive Drug Production License" from the Shandong Provincial Drug Administration. This license is expected to have no significant impact on the company's current performance, and the commercial production of Fluorine-18 labeled somatostatin injection will commence after obtaining the drug marketing approval number [1]. Group 1 - Dongcheng Pharmaceutical's subsidiary, Lanacheng, has received a production license for radioactive drugs [1] - The company anticipates that this development will not significantly affect its current performance [1] - Commercial production of Fluorine-18 labeled somatostatin injection is contingent upon obtaining the necessary marketing approval [1]